Abrams, D. (2017). Medical Marijuana Cures Cancer? Interview with Dr. Donald Abrams. Medical Marijuana and CBD Oil Expert: Dr. Rachna Patel. Youtube, Jan 3, 2017. Retrieved from: https://www.youtube.com/watch?v=JqP7zVTl1Eg
Abuhasira, R., Schleider, L.B., Mechoulam, R., & Novack, V. (2018). Epidemiological Characteristics, Safety and Efficacy of Medical Cannabis in the Elderly. European Journal of Internal Medicine, 49, 44-50.
Ahn, K., McKinney, M.K. & Cravatt, B.F. (2008). Enzymatic Pathways that Regulate Endocannabinoid Signaling in Nervous System. Chemical Reviews, 108(5), 1607-1707.
Aso, E. & Ferrer, I. (2016). CB2 Cannabinoid Receptor as a Potential Target Against Alzheimer’s Disease. Frontiers in Neuroscience, 10, 1-10.
Atwood, B.K. & Mackie, K. (2010). CB2: A Cannabinoid Receptor With An Identity Crisis. British Journal of Pharmacology, 160(3), 467-79.
Benito, C., Tolon, R.M., Pazos, M.R., Nunez, E., Castillo, A.I. & Romero, J. (2008). Cannabinoid CB2 Receptors in Human Brain Inflammation. British Journal of Pharmacology, 153(2), 277-85.
Bergamaschi, M.M., Queiroz, R.H., Zuardi, A.W. & Crippa, J.A. (2011). Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent, Current Drug Safety, 6, 237–249.
Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D.E., Brandi, I.,…& Di Marzo, V. (2001). Molecular Targets for Cannabidiol and its Synthetic Analogues: Effect on Vanilloid VR1 Receptors and on the Cellular Uptake and Enzymatic Hydrolysis of Anandamide. British Journal of Pharmacology, 134, 845-852.
Brose, S.A., Gorlovka, S.A. & Golovko, M.Y. (2016). Brain 2-Arachidonoylglycerol Levels are Dramatically and Rapidly Increased Under Acute Ischemia-injury Which is Prevented by Microwave Irradiation. Lipids, (51)4, 487-495.
Claessens, P., Menten, J., Schotsman, P. & Broeckaert, B. (2008). Palliative Sedation: A Review of the Research Literature. Journal of Pain and Symptom Management, 36(3), 310-333.
Costa, B., Giagnoni, G., Franke, C., Trovato, A.E. & Colleoni, M. (2004). Vanilloid TRPV1 Receptor Mediates the Antihyperalgesic Effect of the Non-psychoactive Cannabinoid, Cannabidiol in a Rat Model of Acute Inflammation. British Journal of Pharmacology, 143, 247-250.
Currow, D.C., Abernathy, A.P., Fallon, M. & Portenoy, R.K. (2017). Repurposing Medications For Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto For Change. Journal of Pain and Symptom Management, 53(3), 533-539.
De La Cruz, M., Ransing, V., Yennu, S., Wu, J., Liu, D., Akhila…& Bruera, E. (2015). The Frequency, Characteristics, and Outcomes Among Cancer Patients With Delirium Admitted to an Acute Palliative Care Unit. The Oncologist, 20, 1425-1431.
Devane, W. A., Dysarz, F.A. III, Johnson, M.R., Melvin, L.S. & Howlett, A. C. (1988). Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Molecular Biology, 34(5), 605-613.
Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffing, F., Gibson, D.,…& Mechoulam, R. (1992). Isolation and Structure of a Brain Constituent that binds to a Cannabinoid Receptor, Science, 258, 1946-1949.
Devinsky, O., Marsh, E. & Friedman, D. et al. (2016). Cannabidiol in Patients with Treatment Resistant Epilepsy: An Open-label Interventional Trial. Lancet Neurology, 15, 270–278.
Devitt-Lee, A. (2015). CBD-drug Interactions: Role of Cytochrome P450. Project CBD, September 8, 2015. Retrieved from: https://www.projectcbd.org/science/cannabis-pharmacology/cbd-drug-interactions-role-cytochrome-p450
Di Marzo, V., Melk, D., Bisogno, T. & De Petrocellis, L. (1998). Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action. Trends in Neurosciences, 21(12), 521-528.
Fernandez-Ruiz, J., Sagreo, O., Pazos, M.R., Garcia, C., Pertwee, R., Mechoulam, R. & Martinez-Orgando, J. (2013). Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applications for this Phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 322-333.
Franken, L.G., De Winter, B.C.M., Van Esch, H.J., Van Zuylen, L., Baar, F.P.M., Tibboel, D. & Koch, B.C.P. (2016). Pharmacokinetic Considerations and Recommendations in Palliative Care, with Focus on Morphine, Midazolam and Haloperidol. Expert Opinion on Drug Metabolism & Toxicology, (12)6, 669-680.
Franz, C.A., & Frishman, W.H. (2016). Marijuana Use and Cardiovascular Disease. Cardiology in Review, 24(4), 58-62.
Freemon, F.R. (1981). Delirium and Organic Psychosis. Pg. 81-94 in Organic mental disease. Jamaica, NY: SP Medical and Scientific Books.
Fujii, M., Sherchan, P., Krafft, P.R., Rolland, W.B., Soejima, Y. & Zhang, J.H. (2014). Cannabinoid Type 2 Receptor Stimulation Attenuates Brain Edema by Reducing Cerebral Leukocyte Infiltration Following Subarachnoid Hemorrhage in Rats. Journal of the Neurological Sciences, 342(0), 101-106.
Gaston, T., Bebin, E., Szaflarski, J. (2016). Importance of Monitoring Clobazam and N- Desmethylclobazam Levels in Treatment with Cannabidiol (CBD) for Epilepsy. Neurology, 86(16), abstract.
Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.Z., Xie, X.Q.,…& Zimmer, A. (2008). Beta-caryophyllene is a Dietary Cannabinoid. Proceedings of the National Academy of Sciences of the United States of America, 105(26), 9099-9104.
Golech, S.A., McCarron, R.M., Chen, Y., Bembry, J., Lenz, F., Mechoulam, R.,…& Spatz, M. (2004). Human Brain Endothelium: Coexpression and Function of Vanilloid and Endocannabinoid Receptors. Brain Research. Molecular Brain Research, 132(1), 87-92.
Haig S. (2009). Diagnosing Dying: Symptoms and Signs of End-Stage Disease. End of Life Care, 2009, 3(4), 8–13.
Hampson, A.J., Grimaldi, M., Axelrod, J. & Wink, D. (1998). Cannabidiol and Delta-9-tetrahydrocannabinol are Neuroprotective Anti-oxidants. Proceedings of the National Academy of Sciences, 95(14), 8268–8273.
Hampson, A.J., Grimaldi, M., Lolic, M., Wink, D., Rosenthal, R. & Axelrod, J. (2000). Neuroprotective Antioxidants from Marijuana. Annals of the New York Academy of Sciences, 899, 274-282.
Hampson et al., Inventors. (2003). Cannabinoids as Antioxidants and Neuroprotectants. US Patent 6,630,507 B1, issued October 7, 2003. The United States of America As Represented by The Department of Health and Human Services, Original Assignee. Retrieved from: https://www.google.ca/patents/US6630507
Hazekamp, A., & Heerdink, E.R. (2013). The Prevalence and Incidence of Medicinal Cannabis on Prescription in The Netherlands. European Journal of Clinical Pharmacology, 69(8), 1575-1580.
Henry, B. (2016). A Systematic Literature Review on the Ethics of Palliative Sedation: An
Update. Current Opinion in Supportive and Palliative Care, 10(3), 201–207.
Hind, W., Tufarelli, C., Neophytou, M., Anderson, S.I., England, T.J. & O’Sullivan, S.E. (2015). Endocannabinoids Modulate Human Blood-Brain Barrier Permeability In Vitro. British Journal of Pharmacology, 172, 3015-3027.
Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P. & Devane, W.A. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacological Reviews, 54(2), 297-302.
Howlett, A.C., Reggio, P.H., Childers, S.R., Hampson, R.E., Ulloa, N.M., Deutch, D.G. (2011). Endocannabinoid Tone Versus Constitutive Activity of Cannabinoid Receptors. British Journal of Pharmacology, 163(7), 1329-1343.
Hu, G., Ren, G. & Shi, Y. (2011). The Putative Cannabinoid Receptor GPR55 Promotes Cancer Cell Proliferation. Oncogene, 30,139-141.
IAHPC List of Essential Medicines for Palliative Care. (2017). Houston: International Association for Hospice and Palliative Care.
Iffland, K. & Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2(1), 139-154.
Irwin, S.A., Pirrello, D., Hirst, J.M., Buckholz, G.T. & Ferris, F.D. (2013). Clarifying Delirium Management: Practical, Evidence-Based Expert Recommendations for Clinical Practice. Journal of Palliative Medicine, 16(4), 423-435.
Jones, R.T. (2002). Cardiovascular System Effects of Marijuana. Journal of Clinical Pharmacology, 42(11 Suppl), 58S-63S.
Joy, J.E., Watson, S.J. & Benson, J.A., eds. (1999). Marijuana and Medicine: Assessing the Science Base. Washington DC: Institute of Medicine National Academy Press.
Land, D. (2017). The Cannabis & Pesticide Controversy: What You Need to Know. Online Presentation, Green Flower Media (www.learngreenflower.com). Original date of 2017 lecture unavailable. Retrieved from: https://www.learngreenflower.com/courses/117/the-cannabis-pesticide-controversy-what-you-need-to-know
Lawlor, P.G., Gagnon, B., Mancini, I.L., Pereira, J.L., Hanson, J., Suarez-Almazor, M.E. & Bruera, E.D. (2000). Occurrence, Causes, and Outcome of Delirium in Patients with Advanced Cancer. Archives of Internal Medicine, 160, 786-794.
Lee, Martin A. (2011). CBD: How it Works. O’Shaughnessy’s, Autumn, 2011.
Lee, Martin A. (2017). How CBD Works. Presentation at “The CBD Summit”, a livestream event associated with Green Flower Media (www.learngreenflower.com), August 10. Retrieved from: https://www.learngreenflower.com/courses/125/the-cbd-summit-get-the-411-on-cbd-straight-from-the-experts
Leker, R.R., Gai, N., Mechoulam, R. & Ovadia, H. (2003). Drug-induced Hypothermia Reduces Ischemic Damage: Effects of the Cannabinoid HU-210. Stroke, 34(8), 2000-2006.
Leker, R.R. & Shohami, E. (2002). Cerebral Ischemia and Trauma-Different Etiologies Similar Mechanisms: Neuroprotective Opportunities. Brain Research. Brain Reviews, 39(1), 55-73.
Long, J.Z., Nomura, D.K., Vann, R.E., Walentiny, D.M., Booker, L., Jin, X.,…& Cravatt, B.F. (2009). Dual Blockade of FAAH and MAGL Identifies Behavioral Processes Regulated by Endocannabinoid Crosstalk In Vivo. Proceedings of the National Academy of Science of the United States of America, (106)48, 20270-20275.
Lu, H. & Mackie, K. (2016). An Introduction to the Endocannabinoid System. Biological Psychiatry, 79(7), 516-525.
Lutz, B., Marsicano, G., Maldonado, R. & Hillard, C.J. (2015). The Endocannabinoid System in Guarding Against Fear, Anxiety, and Stress. Nature Science Reviews, 16(12), 705-718.
Maccarrone, M., Bab, I., Biro, T., Cabral, G., Dey, S.K., Di Marzo, V.,...& Zimmer, A. (2015). Endocannabinoid Signaling at the Periphery: 50 Years After THC. Trends in Pharmacological Sciences, 36(5), 277–296.
Maccarrone, M. & Finazzi-Agro, A. (2003). The Endocannabinoid System, Anandamide, and the Regulation of Mammalian Cell Apoptosis. Cell Death and Differentiation, 10, 946-955.
Mahvan, T.D., Hilaire, M.L., Mann, A., Brown, A., Linn, B., Gardner, T., & Lai, B. (2017). Marijuana Use in the Elderly: Implications and Considerations. Consultant Pharmacist Forum, 32(6), 341-351.
Maltoni, M., Scarpi, E. & Nanni, O. (2014). Palliative Sedation for Intolerable Suffering. Current
Maresz, K., Ponomarev, E.D., Carrier, E.J., Hillard, C.J. & Dittel, B.N. (2005). Modulation of the Cannabinoid CB2 Receptor in Microglial Cells in Response to Inflammatory Stimuli. Journal of Neurochemistry, 95(2), 437-445.
Marijuana in Combination with Opioids in Palliative and Hospice Patients, Clinical Trial. (2017). Current page on U.S. National Library of Medicine ClinicalTrails.gov website (page last updated 08/31/2017). Information on page provided by (Responsible Party): Theodore Zanker MD, The Connecticut Hospice Inc. Retrieved from: https://clinicaltrials.gov/ct2/show/NCT03233633
Martin, A. (2017, August 22). This Hospice Is Hoping to Prove That Cannabis Can Make Dying Less Painful. BuzzFeed News. Retrieved from: https://www.buzzfeed.com/alysonmartin/this-hospice-is-hoping-to-prove-that-cannabis-can-make?utm_term=.kapgo4ALY#.ctOE3k78Y
McPartland, J.M., Guy, G.W. & Di Marzo, V. (2014). Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. Plos One, 9(3), 1-21.
McPartland, J.M. & Pruitt, P.L. (1997). Medical Marijuana and its Use by the Immunocompromised. Alternative Therapies in Health and Medicine, 3(3), 39-45.
McPartland, J.M. & Russo, E.B. (2001). Cannabis and Cannabis Extracts: Greater than the Sum of Their Parts? Journal of Cannabis Therapeutics (The Haworth Press, Inc.), 1(3/4), 103-132.
Mechoulam, R. (2010). Head Trauma, Neuroprotection, and Cannabinoids. Presentation at The Sixth National Clinical Conference on Cannabis Therapeutics, April 16-17, 2010, Warwick, Rhode Island. Retrieved from https://www.youtube.com/watch?v=RU68-SRNPOg
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N., Schatz, A.,…& Compton, D. et al. (1995). Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, that Binds to Cannabinoid Receptors. Biochemical Pharmacology, 50(1):83-90.
Mechoulam, R., Panikashvili, D. & Shohami, E. (2002). Cannabinoids and Brain injury: Therapeutic Implications. Trends in Molecular Medicine, 8(2):58-61.
More, S.V.& Choi, D.K. (2015). Promising Cannabinoid Based Therapies for Parkinson’s Disease:
Motor Symptoms to Neuroprotection. Molecular Neurodegeneration, 10(17), 1-26.
Moriera, F.A. & Crippa, J.A. (2009). The Psychiatric Side-effects of Rimonabant. Revista Brasiliera Psiquiatria, 31(2), 145-153.
Munro, S., Thomas, K.L. & Abu-Sharr, M. (1993). Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature, 365, 61-65.
Najjar, S., Pearlman., Alper, K., Najjar, A. & Devinsky, O. (2013). Neuroinflammation and Psychiatric Illness. Journal of Neuroinflammation, 10(43), 1-24.
Pancher, P. & Hasko, G. (2008). Endocannabinoids and Cannabinoid Receptors in Ischaemia-Reperfusion Injury and Preconditioning. British Journal of Pharmacology, 153(2), 252-262
Parker, Linda. (2017). Cannabinoids and the Brain. Cambridge, MA: The MIT Press.
Pertwee, R.G. (2008). Ligands That Target Cannabinoid Receptors in the Brain: From THC to Anandamide and Beyond. Addiction Biology, 13(2), 147-159.
Petrosino, S., Ligresti, A. & Di Marzo, V. (2009). Endocannabinoid Chemical Biology: A Tool for the Development of Novel Therapies. Current Opinion in Chemical Biology, 13(3), 309-320.
Pype, P., Teuwen, I., Mertens, F., Sercu, M. & De Sutter, A. (2017). Suboptimal Palliative Sedation in Primary Care: An Exploration. Acta Clinica Belgica, June 5, 1-8.
Ruchlemer, R., Amit-Kohn, M., Raveh, D., & Hanus, L. (2015). Inhaled Medicinal Cannabis and the Immunocompromised Patient. Supportive Care in Cancer, 23(3):819-22.
Russo E.B. (2001). Hemp for Headache: An In-depth Historical and Scientific Review of Cannabis in Migraine Treatment. Journal of Cannabis Therapeutics, 1, 21–92.
Russo, E.B. (2015). Synthetic and Natural Cannabinoids: The Cardiovascular Risk. The British Journal of Cardiology, Editorial, 22(1), 7-9.
Russo, E.B. (2016a). The Endocannabinoid System in Health and Disease. Presentation at The United In Compassion Medicinal Cannabis Symposium, June 14th & 15th, Sydney, Australia. Retrieved from: https://www.youtube.com/watch?v=1s-dDGTt20c&index=3&list=PL9Eh5xA-yu4ZUfSi-jQD-kWsMN3EOG5eb&t=23s
Russo, E.B. (2016b). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences, 37(7), 594-605.
Russo, E.B & Guy, G.W. (2006). A Tale of Two Cannabinoids: The Therapeutic Rationale for Combining Tetrahydrocannabinol and Cannabidiol. Medical Hypotheses, 66(2), 234-46.
Santosh, V. & Sravya, P. (2017). Glioma, Glutamate (SLC7A11) And Seizures-A Commentary. Annals of Translational Medicine, 5(10), 214.
Scotter, E.L., Abood, M.E. & Glass, M. (2010). The Endocannabinoid System as a Target for the
Treatment of Neurodegenerative Disease. British Journal of Pharmacology, 160(3),
480-498.
Shi, S., & Klotz, U. (2011). Age-Related Changes in Pharmacokinetics. Current Drug Metabolism, 12(7), 601-10.
Shohami, E., Cohen-Yeshurun, A., Magid, L., Algali, M. & Mechoulam, R. (2011). Endocannabinoids and Traumatic Brain Injury. British Journal of Pharmacology, 163(7), 1402-1410.
Singh G., Rees J.H. & Sander, J.W. (2007). Seizures and Epilepsy in Oncological Practice: Causes, Course, Mechanisms and Treatment. Journal of Neurology, Neurosurgery and Psychiatry, 78(4), 342–9.
Sizoo, E.M., Braam, L., Postma, T.J., Roeline, H., Pasman, W., Heimans…& Taphoorn, M.J.B. (2010). Symptoms and Problems in the End-of-life Phase of High Grade Glioma Patients. Neuro-Oncology, 12(11), 1162-1166.
Sugiura, T. & Waku, K. (2000). 2-Arachidonoylglycerol and the Cannabinoid Receptors. Chemistry and Physics of Lipids, 108(1-2), 89-106.
Sulak, D., Saneto, R. & Goldstein, B. (February 28, 2017). Medical Marijuana for Seizures. Published on projectcbd.org. Retrieved from: https://www.projectcbd.org/article/medical-marijuana-seizures-sulak-saneto-goldstein
Theisen, Eloise. (2017). Cannabis for Seniors: Reducing Pharmaceuticals and Improving Quality of Life. Green Flower Media (www.learngreenflower.com). Original date of 2017 lecture unavailable. Retrieved from: https://www.learngreenflower.com/courses/63/Cannabis-For-Seniors-Reducing-Pharmaceuticals-and-Improving-Quality-of-Life
Torres, A., Linker, W., Land, D., & Gaudino, R. (2017). Study of Pesticides in Clones: Research Summary. Published by Steep Hill Labs, Inc., September 22. Retrieved from: https://landing.steephill.com/cleanclones
Tradounsky, G. (2013). Seizures in Palliative Care. Canadian Family Physician, 59(9), 951-955.
The United States of America As Represented by the Department of Health and Human Services, Original Assignee. Medicinal Acidic Cannabinoids. US patent 7807711 B2, issued January 27, 2011. Retrieved from: https://www.google.ch/patents/US7807711
Waldman, M., Hochhauser, E., Fishbein, M., Aravot, D., Shainberg., A. & Sarne, Y. (2013). An Ultra-low Dose of Tetrahydrocannabinol Provides Cardioprotection. Biochemical Pharmacology, 85(11), 1626-33.
Wallace, M., Martin, B. & DeLorenzo, R.J. (2002). Evidence for a Physiological Role of Endocannabinoids in Modulation of Seizure Threshold and Severity. European Journal of Pharmacology, 452, 295-301.
World Health Organization Essential Medicines in Palliative Care, Executive Summary. (2013). Houston: International Association for Hospice and Palliative Care.
Zendulka, O., Dovrtelova, G., Noskova, K., Turjap, M., Sulcova, A., Hanus, L., & Jurica, J. (2016). Cannabinoids and Cytochrome P450 Interactions. Current Drug Metabolism, 17(3), 206-226.
REFERENCES-Difficult Road Of Dying